JADE3 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 human near-haploid cell line, designed for targeted disruption of the JADE3 gene. This heterogeneous pool provides a robust loss-of-function model for studying JADE3-dependent pathways without clonal selection. The CRISPR/Cas9-mediated gene disruption introduces mutations that ablate JADE3 protein expression, enabling functional interrogation of its role in chromatin regulation and leukemia biology.
HAP1 is a near-haploid cell line derived from KBM-7 chronic myeloid leukemia cells, exhibiting fibroblast-like morphology but retaining hematopoietic origin. Its haploid genome facilitates unambiguous genotype-phenotype correlations, making it a favored platform for functional genomics and CRISPR screening. Widely applied in cancer research, HAP1 cells enable direct investigation of signaling networks and gene functions relevant to leukemia, providing a physiologically pertinent context for knockout studies.
JADE3 encodes a scaffold protein integral to the HBO1 histone acetyltransferase (HAT) complex, which includes the catalytic subunit HBO1 (KAT7), adaptors ING4/5, and cofactors MEAF6 and EAF6. This complex acetylates histone H3 at lysine 14 (H3K14) and histone H4 at lysine 5 (H4K5), promoting chromatin relaxation and transcriptional activation. JADE3 orchestrates complex assembly and substrate targeting, thereby regulating gene expression programs involved in DNA replication, cell cycle progression, and differentiation. Upstream, JADE3 is controlled by developmental signals governing HBO1 complex expression, while downstream acetylation events influence cellular proliferation and differentiation pathways.
In HAP1 leukemia cells, JADE3 disruption permits dissection of HBO1 complex functions in hematopoietic malignancy. Epigenetic dysregulation is central to leukemogenesis, and loss of JADE3-mediated histone acetylation enables assessment of oncogenic dependencies on this complex. The haploid background ensures complete gene knockout, yielding unambiguous phenotypic outcomes and facilitating drug target validation and mechanistic studies of epigenetic inhibitors in a cancer-relevant cellular environment.
These polyclonal knockout cells support diverse research applications, including functional characterization of the HBO1 complex, investigation of histone acetylation dynamics in leukemia, and validation of epigenetic drug targets. Key assays include Western blotting for H3K14ac and H4K5ac, ChIP-qPCR for HBO1 occupancy, co-immunoprecipitation of complex components, proliferation and cell cycle assays, and RNA-seq transcriptomics. For technical inquiries or ordering, please contact Ascent Research.
